Ephedra hearings
This article was originally published in The Tan Sheet
Executive Summary
House Energy & Commerce Committee/Subcommittee on Oversight & Investigations plans second day of hearings on botanical July 24, following previously-announced July 23 session (1"The Tan Sheet" July 14, 2003, In Brief). Hearings will take place in room 2123 in the Rayburn office building...
You may also be interested in...
Metabolife execs subpoenaed
House Energy & Commerce Subcommittee on Oversight & Investigations authorizes issuance of three subpoenas to former and current Metabolife employees in 9-0 vote. During business meeting held July 10, Rep. Greg Walden (R-Ore.) noted that in response to hearing invitation letters sent to 13 individuals, three Metabolife witnesses "have sent written responses through their respective counsels declining the invitation to testify." Founder, co-owner and former president Michael Ellis, former president David Brown and current employee Daniel Rodriguez will be issued subpoenas "as quickly as possible," committee says. In response, Metabolife maintains it is cooperating with House investigation and "looks forward to having its senior officials, including" CEO Russell Schreck, testify. First of two hearings on ephedra is scheduled for July 23; House inquiry began in February (1"The Tan Sheet" March 3, 2003, p. 9)...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.